Respiratory

Back to articles

Roflumilast: Lower cardiovascular event rates in COPD

KEY POINT

Patients with chronic obstructive pulmonary disease (COPD) demonstrated a lower incidence of cardiovascular events when treated with roflumilast (Daliresp—Forest Pharmaceuticals) versus placebo, according to a post-hoc analysis of randomized trials.